Author: Rajesh Chatha, Hridesh Chatha / Editor: Rajesh Chatha, Robert Hirst / Codes: GP6, SLO10 / Published: 22/04/2021

At TERN Education we are keen to help you all learn how to critically evaluate the evidence base behind your practice. In order to do this, we are producing monthly ‘virtual’ journal club modules on RCEMLearning. It’s like a critical appraisal paper you can do in your own time! It allows you the opportunity to practice and learn critical appraisal in a relaxed environment and you get a certificate for the old portfolio! When you finish, click the link to the forum to discuss this month’s paper with colleagues around the country.

Interested in writing a module? We are looking to recruit regional teams to write future modules from August. Email us on [email protected].

References

  1. Hunt, B.J. (2015), The current place of tranexamic acid in the management of bleeding. Anaesthesia, 70: 50-e18.
  2. CRASH-2 trial collaborators et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010 Jul 3;376(9734):23-32.
  3. CRASH-3 trial collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet (London, England) vol. 394,10210 (2019): 1713-1723.
  4. Post, René et al. Ultra-early tranexamic acid after subarachnoid haemorrhage (ULTRA): a randomised controlled trial. Lancet. 2021 Jan 9;397(10269):112-118.
  5. Reuben, Adam et al. Novel use of tranexamic acid to reduce the need for Nasal Packing in Epistaxis (NoPac) randomised controlled trial: research protocol. BMJ open vol. 9,2 e026882. 15 Feb. 2019.
  6. HALT-IT Trial Collaborators. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet (London, England) vol. 395,10241 (2020): 1927-1936.